Related Experiment Video
Updated: Jun 15, 2026
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
Published on: September 9, 2022
Preclinical evaluation of ELP-004 in mice
Jamie L McCall1,2, Werner J Geldenhuys3, Lisa J Robinson4
1Department of Microbiology, Immunology, and Cell Biology, West Virginia University School of Medicine, Morgantown, West Virginia, USA.
Abstract:
This study provides a detailed understanding of the preclinical pharmacokinetics and metabolism of ELP-004, an osteoclast inhibitor in development for the treatment of bone erosion. Current treatments for arthritis, including biological disease-modifying antirheumatic drugs, are not well-tolerated in a substantial subset of arthritis patients and are expensive; therefore, new treatments are needed. Pharmacokinetic parameters of ELP-004 were tested with intravenous, oral, and subcutaneous administration and found to be rapidly absorbed and distributed. We found that ELP-004 was non-mutagenic, did not induce chromosome aberrations, non-cardiotoxic, and had minimal off-target effects. Using in vitro hepatic systems, we found that ELP-004 is primarily metabolized by CYP1A2 and CYP2B6 and predicted metabolic pathways were identified. Finally, we show that ELP-004 inhibits osteoclast differentiation without suppressing overall T-cell function. These preclinical data will inform future development of an oral compound as well as in vivo efficacy studies in mice.
Insights
ELP-004, an investigational osteoclast inhibitor, shows promising preclinical results for treating bone erosion. It is rapidly absorbed, safe, and selectively inhibits osteoclasts without impacting T-cell function, supporting further development.
Area of Science:
- Pharmacology and Toxicology
- Immunology
- Drug Development
Background:
- Current arthritis treatments, including biologic disease-modifying antirheumatic drugs, have limitations in tolerability and cost.
- There is a significant unmet need for novel therapeutics for bone erosion associated with conditions like arthritis.
Purpose of the Study:
- To characterize the preclinical pharmacokinetics and metabolism of ELP-004, a novel osteoclast inhibitor.
- To evaluate the safety profile and mechanism of action of ELP-004 in preclinical models.
Main Methods:
- Pharmacokinetic studies were conducted following intravenous, oral, and subcutaneous administration of ELP-004.
- In vitro assays assessed mutagenicity, chromosomal aberrations, cardiotoxicity, off-target effects, and hepatic metabolism (CYP1A2, CYP2B6).
- ELP-004's effect on osteoclast differentiation and T-cell function was evaluated.
Main Results:
- ELP-004 demonstrated rapid absorption and distribution across tested administration routes.
- Preclinical safety assessments revealed ELP-004 to be non-mutagenic, non-cardiotoxic, with minimal off-target effects.
- ELP-004 selectively inhibits osteoclast differentiation via CYP1A2 and CYP2B6 metabolism, without suppressing T-cell function.
Conclusions:
- ELP-004 exhibits favorable preclinical pharmacokinetic and safety profiles.
- The compound effectively inhibits osteoclast differentiation, presenting a potential new therapeutic strategy for bone erosion.
- These findings support the continued development of ELP-004, including oral formulations and in vivo efficacy studies.
More Related Videos
08:05Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice
Published on: March 1, 2017
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
